Maintains Buy
Monday, July 29, 2019
Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi
Lexicon Pharmaceuticals LXRX 67.84% shares plummeted after the company received a written notice from Sanofi SNY 2.49% terminating the agreement for the development and commercialization of the company’s Diabetes drug candidate Sotagliflozin.
Lexicon Pharmaceuticals shares were trading were trading down 47.45% at $2.99 in Monday’s pre-market session. The stock has a 52-week high of $12.95 and a 52-week low of $4.25.
Genomic Health EPS beats by $0.07, beats on revenue
Genomic Health (NASDAQ:GHDX): Q2 GAAP EPS of $0.42 beats by $0.07.
Revenue of $114.14M (+19.4% Y/Y) beats by $3.36M.
Dr. Reddy’s misses on revenue
Dr. Reddy’s (NYSE:RDY): Q1 GAAP EPS of $0.58.
Revenue of $558M (+3.3% Y/Y) misses by $21.74M.
uniQure EPS misses by $0.08, beats on revenue
uniQure (NASDAQ:QURE): Q2 GAAP EPS of -$0.83 misses by $0.08.
Revenue of $2.47M (-19.0% Y/Y) beats by $0.98M.
Shares +0.82% PM.
Subscribe to:
Posts (Atom)